Why Should We Advocate Maternal Immunization?

Boonyaratanakornkit, Jim; Chu, Helen Y.

doi:10.1097/inf.0000000000002312

Cited by 12 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No conclusive data has been published regarding specific newborn passive immunity, consisting in the transplacental immunoglobulin G (IgG) antibodies passage from the affected mother to her fetus during pregnancy, following the kinetics model well studied in maternal vaccination (dTpa and influenza immunization) during pregnancy 15,16 …”

Section: Introductionmentioning

confidence: 99%

Passive immunity in newborn from SARS‐CoV‐2‐infected mother

Cavaliere

Marchi

Aquilini

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vertical transmission is an open issue. Recent reports call into question in utero or peripartum viral transmission to the offspring. Few data are available on immunoglobulin G (IgG) and/or IgM in newborns. Insufficient evidence is available regarding passive immunity in neonates born from SARS‐CoV‐2 infected women. We report a case of a neonate showing the presence of blood specific IgG and the absence of IgM and negative nasopharyngeal swab. He was born from an asymptomatic SARS‐CoV‐2‐infected mother with positive IgG and IgM. The transplacental passage of specific IgG antibodies from the affected mother to the unaffected fetus highlights neonatal passive immunity.

show abstract

Section: Introductionmentioning

confidence: 99%

Passive immunity in newborn from SARS‐CoV‐2‐infected mother

Cavaliere

Marchi

Aquilini

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Moreover, the theoretical risk of specific vaccine-associated enhanced respiratory disease (VAERD) could be circumvented. Lastly, a direct boost to the immunosuppressed pregnant mother could provide a benefit to the mother, who is immunologically at-risk during this time [63].…”

Section: Discussionmentioning

confidence: 99%

Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs

et al. 2021

View full text Add to dashboard Cite

One approach to protect new-borns against respiratory syncytial virus (RSV) is to vaccinate pregnant women in the last trimester of pregnancy. The boosting of circulating antibodies which can be transferred to the foetus would offer immune protection against the virus and ultimately the disease. Since non-human primates (NHPs) have similar reproductive anatomy, physiology, and antibody architecture and kinetics to humans, we utilized this preclinical species to evaluate maternal immunization (MI) using an RSV F subunit vaccine. Three species of NHPs known for their ability to be infected with human RSV in experimental challenge studies were tested for RSV-specific antibodies. African green monkeys had the highest overall antibody levels of the old-world monkeys evaluated and they gave birth to offspring with anti-RSV titers that were proportional to their mother. These higher overall antibody levels are associated with greater durability found in their offspring. Immunization of RSV seropositive AGMs during late pregnancy boosts RSV titers, which consequentially results in significantly higher titers in the vaccinated new-borns compared to the new-borns of unvaccinated mothers. These findings, accomplished in small treatment group sizes, demonstrate a model that provides an efficient, resource sparing and translatable preclinical in vivo system for evaluating vaccine candidates for maternal immunization.

show abstract

“…A number of RSV maternal vaccines, most of them nonadjuvanted, are currently in clinical development (Table 2). 48 Older infants and children younger than 2 years Although the peak of severe RSV disease is within the first 3 to 4 months of life, RSV also causes significant disease in older infants and toddlers. Globally, more than half of hospitalizations for acute RSV LRTIs and RSV-related deaths occur in children older than 6 months.…”

Section: Infants Younger Than 4 To 6 Monthsmentioning

confidence: 99%

The journey to a respiratory syncytial virus vaccine

Mejías

Rodríguez‐Fernández

Oliva

et al. 2020

Annals of Allergy, Asthma & Immunology

104

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a major global health problem associated with significant morbidity and mortality in low-and middle-income countries.There are several vaccine candidates in the pipeline directed toward different target populations: infants younger than 6 months, children older than 6 months to 2-to 5-year-old children, and the elderly.To protect the young infant from severe RSV infection, a combined strategy using passive and active immunization with maternal vaccination and high-potency, extended half-life monoclonal antibodies may be needed.Vaccines will have the opportunity to decrease not only the burden of acute RSV disease but also the long-term respiratory morbidity associated with this infection.

show abstract

Why Should We Advocate Maternal Immunization?

Cited by 12 publications

References 63 publications

Passive immunity in newborn from SARS‐CoV‐2‐infected mother

Passive immunity in newborn from SARS‐CoV‐2‐infected mother

Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs

The journey to a respiratory syncytial virus vaccine

Contact Info

Product

Resources

About